Neoadjuvant

89% estimated event-free survival at one year among patients with stage II to IV resectable CSCC who received Libtayo prior to surgery in a Phase 2 trial No disease recurrence among the…

At the American Society of Clinical Oncology (ASCO) annual meeting, researchers reported on a…

CHICAGO -- Neoadjuvant chemotherapy failed to match upfront surgery for survival in resectable pancreatic cancer,…

Neoadjuvant treatment with olaparib (Lynparza) prior to surgical resection and adjuvant chemotherapy was…

In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical, combination of nivolumab plus…

In this exclusive roundtable video from MedPage Today, three expert leaders in the field of bladder cancer…

Patients with operable non-small cell lung cancer (NSCLC) had a 5-year overall survival (OS)…

At this year's American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, results…

Neoadjuvant immunotherapy with PD-1 inhibitors led to objective responses in 85% of patients…

SAN ANTONIO -- A novel neoadjuvant regimen for HER2-negative breast cancer doubled the pathologic complete response (pCR) rate…